Neuroscientific Biopharmaceuticals Ltd. · ASX:NSB
Neuroscientific Biopharmaceuticals — TechKnow Invest Roadshow 2019
21 slides from Neuroscientific Biopharmaceuticals's conference presentation, Mar 19, 2019
Slide 1: NeuroScientific to present at The TechKnow Invest Roadshow
ASX ANNOUNCEMENT ASX:NSB For personal use only NeuroScientific to present at The TechKnow Invest Roadshow Perth, Australia; 19 March 2019 – Mr Brian Leedman, Chairman of NeuroScientific Biopharmaceuticals Limited (ASX:NSB) will present a business update at the TechKnow Invest Roadshow commencing in
Slide 2: NeuroScientific Biopharmaceuticals Ltd
For personal use only NeuroScientific Biopharmaceuticals Ltd ASX.NSB Novel drug therapies for neurodegenerative conditions
Slide 3: Disclaimer
DISCLAIMER For personal use only The purpose of the presentation is to provide an update of the business of NeuroScientific Biopharmaceuticals Ltd (“NeuroScientific”, or “the Company”). These slides have been prepared as a presentation aid only and the information they contain may require further ex
Slide 4: 'Big Pharma Has Struck Out'
‘BIG PHARMA HAS STRUCK OUT’ 3 For personal use only
Slide 5: Company Highlights
4 COMPANY HIGHLIGHTS For personal use only Advanced preclinical lead drug candidate with multiple treatment indications Strong strategic partnerships geared towards success Validated strategy and business model Experienced board and management team
Slide 6: Leadership Team
5 Leadership Team For personal use only BRIAN LEEDMAN MATT LIDDELOW ANTON UVAROV PhD STEPHEN QUANTRILL Co-founder of ResApp 12+ years experience Founding director of 20 years’ experience in Health Ltd (ASX.RAP), commercialising medical Actinogen Medical corporate advisory and Imugene Ltd (ASX:IMU) a
Slide 7: Treatment Markets with Unmet Need
6 TREATMENT MARKETS WITH UNMET NEED For personal use only Alzheimer’s disease Optic nerve conditions 48M people globally have dementia 5% of population suffer vision loss due to 70% of dementias damaged optic nerve Alzheimer’s disease 60M people US $818B global affected by glaucoma economic burden U
Slide 8: Alzheimer's Disease: The need for novel therapeutics
7 ALZHEIMER’S DISEASE: The need for novel therapeutics For personal use only Drugs targeting the beta-amyloid protein have all failed in late-stage clinical trials… § Pathology of Alzheimer’s disease still not definitive § Drugs may have been administered too late § Patient selection for clinical tr
Slide 9: Alzheimer's Disease: The need for novel therapeutics
ALZHEIMER’S DISEASE: The need for novel therapeutics For personal use only Drugs targeting the beta-amyloid protein have all failed in late-stage clinical trials… § During 2018 alone, Eli Lilly, AstraZeneca, Johnson & Johnson, Merck, and Eisia / Biogen all halted clinical trials § 20-years of resear
Slide 10: Lead Candidate: EmtinB
9 LEAD CANDIDATE: EMTINB For personal use only NOVEL § Modeled on Metallothionein (MT-II) - a well known neuroprotective and neurogenerative brain factor, with EmtinB showing superior drug properties § Binds LRP-1 receptors – novel Mechanism of Action (MOA) § Stops cell death & stimulates regenerati
Slide 11: Evolution of EmtinB
10 EVOLUTION OF EMTINB For personal use only MT-II Structure EmtinB Peptide EmtinB Peptide Dendrimer β-domain α-domain ▹ 61 amino acid length ▹ 14 amino acid length ▹ Synthesised as a ▹ Binds divalent metal ions ▹ Isolated from the β- dendrimer: ▹ Difficult to manufacture domain of MT-II protein § I
Slide 12: EmtinB Mechanism of Action: Binding LRP-1 receptor
11 EMTINB MECHANISM OF ACTION: Binding LRP-1 receptor For personal use only
Slide 13: EmtinB Scientific Data: Preclinical studies
12 EMTINB SCIENTIFIC DATA Preclinical studies For personal use only Increased mean survival of Stimulates neurite brain cells >90% outgrowth by up to 300% Cell survival: 48-hour incubation period Neurite length: 24-hour treatment period EmtinB + 92% EmtinB 225% toxicity Induced Control 100% toxicity
Slide 14: EmtinB Scientific Data: Preclinical studies in AD models
13 EMTINB SCIENTIFIC DATA Preclinical studies in AD models For personal use only Prevented cell death in in vitro Slowed progression of disease Alzheimer’s model of toxicity (memory impairment) by >80% in Alzheimer’s animal model Control 100% Cognition: treatment for 48 days Aβ-42 50% EmtinB 70% +7
Slide 15: Supporting Scientific Data: Regenerating the optic nerve
14 SUPPORTING SCIENTIFIC DATA Regenerating the optic nerve For personal use only ▹ Precursor to EmtinB (MT-II) stimulated regenerative growth of optic nerve after complete surgical transection ▹ Promotes axonal regeneration through an inhibitory environment in vivo Optic Nerve Growth No treatment Tr
Slide 16: EmtinB Development Schedule
15 EMTINB DEVELOPMENT SCHEDULE For personal use only 2019 2019 2019 2019 2019 2019 Q1 Q2 Q3 Q4 Q3 Q4 Alzheimer’s disease indication Preclinical safety & toxicology studies Additional AD animal efficacy study Phase I clinical study Ophthalmology indication Preclinical safety studies Preclinical effic
Slide 17: Strategic Partnerships
16 STRATEGIC PARTNERSHIPS For personal use only ▹ Partner for preclinical studies ▹ Partner for ophthalmology studies ▹ Managed >3300 unique compounds ▹ Developed 1st artificial cornea ▹ >500 IND/CTD programs in the last ▹ Developed 1st transgenic animal 5-years model for macular degeneration ▹ Offe
Slide 18: Business Model
17 BUSINESS MODEL For personal use only ▹ Company will seek to out-license EmtinB for late-stage clinical development ▹ Potential for multiple treatment indications will be attractive to “big pharma”
Slide 19: Key Milestones
18 KEY MILESTONES For personal use only APR -19 MAY / JUNE -19 Report on ocular tissue Results on additional distribution study in efficacy study in CVN rabbits. Alzheimer’s model MAY-19 JUN / JUL -19 Results on efficacy study Expected conclusion of in glaucoma pig model safety & toxicity studies
Slide 20: Corporate Overview
19 CORPORATE OVERVIEW For personal use only Capital Structure ▹ Completed IPO listing on the ASX ASX Code NSB on the 27 July 2018 Shares on Issue 73,580,592 ▹ Lead candidate funded through to Shares Escrowed (12 Months) 1,906,269 Shares Escrowed (24 Months) 19,349,506 completion of Phase I Share Pri
Slide 21: NeuroScientific Biopharmaceuticals Ltd
For personal use only NeuroScientific Biopharmaceuticals Ltd ASX.NSB Novel drug therapies for neurodegenerative conditions
NeuroScientific Biopharmaceuticals — TechKnow Invest Roadshow 2019 on 6ix